

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

IN RE APPLICATION OF: Wang, Kangseng

APPLICATION NO.: 09/781,046

FILED: February 8, 2001

FOR: **A METHOD AND SYSTEM FOR INTRODUCING A GENE INTO A HUMAN STEM CELL**

EXAMINER: Thaian N. Ton

ART UNIT: 1632

RECEIVED

DEC 06 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

BioAgri Corporation, Assignee of

- an undivided share of the entire right, title, and interest
 the entire right, title and interest

in the above-identified patent application by virtue of an Assignment recorded in the U.S. Patent and Trademark Office at Reel 011957, Frame 0382 on July 2, 2001, hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the instant application which would extend beyond the expiration date of the full statutory term defined in 35 USC §154 to §156 and §173, as presently shortened by any terminal disclaimer, of

U.S. Patent Application No. 09/537, 861 filed on March 28, 2000

The owner hereby agrees that any patent so granted on the instant application shall be enforceable only for and during such period that it and the above-listed patents and/or patent applications are commonly owned. This agreement runs with any patent granted on the instant application and is binding upon the grantee, its successors or assigns.

In making the above disclaimer, the owner does not disclaim the terminal part of any patent granted on the instant application that would extend to the expiration date of the full statutory term as defined in 35 USC §154 to §156 and §173 of the above-listed patents and/or applications, as presently shortened by any terminal disclaimer, in the event that said patent(s)/application(s) later: expires for failure to pay a maintenance fee, is held unenforceable, is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR §1.321, has all claims cancelled by a reexamination certificate, is reissued, or is in any manner

terminated prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer.

1. Certification under 37 CFR §3.73(b)

I, the undersigned, am empowered to act on behalf of the assignee. The evidentiary documents referred to above have been reviewed by the undersigned and it is certified that to the best of the Assignee's knowledge and belief, title is in the Assignee seeking to take action.

I declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further, that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

2. Fee Payment

- A check covering the Terminal Disclaimer fee under 37 CFR 1.20 is enclosed:
 - Large entity (\$110.00)
 - Small entity (\$55.00)
- Please charge the above fee, and any other fee necessary for entry of this Terminal Disclaimer, to Deposit Account No. 50-0665.

Respectfully submitted,
Perkins Coie LLP


James J. Zhu, Ph.D.
Registration No.52, 396

Correspondence Address:

Customer No. 34055
Perkins Coie LLP
P.O. Box 1208
Seattle, Washington 98111-1208